🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06563700
Active, not recruiting Not applicable

Novel Lenses for Myopia Progression Trial

NCT06563700 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Eye Disease Prevention and Treatment Center
Phase
Not applicable
Started
2024-08-16
Last updated
2026-04-28

Condition(s) studied

Myopia, Progressive

Investigational drug(s) / intervention(s)

spectacle lenssingle vision lens

spectacle lens: one of ZEISS BD spectacle lens designs 1 to 5

single vision lens: single vision lens

Study summary

This is a multi-center , prospective, randomised, longitudinal study to evaluate rate of myopia progression with novel lenses compared to Single-Vision spectacles. A total of 342 children will be recruited where 57 participants each are randomised to wear one of 5 test spectacle lens designs or a single vision lens (control) for 12 months. At the end of 12 months, those randomised to single vision lenses will be transferred to one of the test lenses and all the groups continued for another 12 months. Myopia progression during the second year with test lenses will be compared to historical or published controls.

Eligibility

Sex
ALL
Min age
7 Years
Max age
13 Years
Healthy volunteers
No
Inclusion Criteria: be accompanied by a parent or guardian who is able to read and comprehend Chinese/English and sign a record of informed consent/assent; at baseline, be within the age range of 7 to 13 years old inclusive; be diagnosed as myopic having cycloplegic spherical equivalent between -0.75 dioptre (D) and -5.00 dioptre (D); astigmatism ≤1.50D; anisometropia of not more than 1.50D; be willing to comply with the wearing of clinical trial spectacles and clinical trial visit schedule as directed by the investigator; have ocular findings deemed to be normal; vision correctable to at least 0.8 or better in each eye with spectacles. Exclusion Criteria: Any pre-existing systemic or ocular condition, including infection or disease that is likely to affect visual acuity and refractive error; Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants. Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology in an adverse or beneficial manner at enrolment and/or during the clinical trial. History of eye trauma Amblyopia Strabismus History of use of myopia control interventions such as Orthokeratology, atropine or eye surgery 6 months prior to commencement of this trial. Known allergy or intolerance to ingredients to cycloplegic eye-drops. Currently enrolled in another clinical trial.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai Eye Disease Prevention and Treatment Center Shanghai China

More Shanghai Eye Disease Prevention and Treatment Center trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06563700 on ClinicalTrials.gov ↗ ← All trials in China